phrykt

Pliant Therapeutics, Inc. (PLRX): who owns it and who trades it

As of Nov 16, 2026, PLRX insiders reported 4 open-market sales worth $164K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bernard Coulie (CEO), with $114K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Pliant Therapeutics

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PLRX

85 funds and institutions reported PLRX shares worth $54.8M at the end of Q2 2026, about 78% of the company. The largest holder is Tang Capital Management LLC with 9.9%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

Tang Capital Management LLC9.9%
ADAR1 Capital Management, LLC8.9%
Vanguard Capital Management LLC3.9%
Acadian Asset Management LLC3.9%
Two Sigma Investments, LP3.7%
Citadel Advisors LLC3.5%
Renaissance Technologies LLC3.3%
Monaco Asset Management SAM3.1%
Lynx1 Capital Management LP2.9%
BML Capital Management, LLC2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Tang Capital Management LLC6.14M9.92%$7MNo change
ADAR1 Capital Management, LLC5.51M8.90%$6.3M+113%
Vanguard Capital Management LLC2.44M3.94%$2.8M+4%
Acadian Asset Management LLC2.42M3.90%$2.7MNo change
Two Sigma Investments, LP2.26M3.65%$2.6M+0%
Citadel Advisors LLC2.14M3.46%$2.4M-34%
Renaissance Technologies LLC2.05M3.31%$2.3M+11%
Monaco Asset Management SAM1.94M3.13%$2.2MNo change
Lynx1 Capital Management LP1.80M2.90%$2MNew
BML Capital Management, LLC1.55M2.50%$1.8MNo change
Prosight Management, LP1.37M2.21%$1.6M-18%
Peapod Lane Capital LLC1.31M2.11%$1.5M+2%
Woodline Partners LP1.30M2.09%$1.5M-22%
BlackRock, Inc.1.15M1.86%$1.3M+5%
Ikarian Capital, LLC1.00M1.62%$1.1MNew
Eversept Partners, LP891,4251.44%$1MNo change
Marshall Wace, LLP835,1241.35%$952K-16%
Redmile Group, LLC772,1261.25%$880KNo change
JPMorgan Chase & Co681,6471.10%$784KNew
Jacobs Levy Equity Management, Inc643,1201.04%$733K-10%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PLRX insiders reported $0 of open-market purchases and $164K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$164K
4 trades, 4 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Jan 20, 2026
Filed Jan 22, 2026

Purchases and sales by month

$164K$164KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jan 20, 2026Keith Lamont CummingsCFOSale plan24,002$1.28$30.7KForm 4
Jan 20, 2026Lily CheungChief Human Resource OffSale plan7,534$1.28$9.6KForm 4
Jan 20, 2026Bernard CoulieCEOSale plan89,375$1.28$114KForm 4
Jan 20, 2026Minnie KuoChief Operating OfficerSale plan6,917$1.28$8.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bernard CouliePresident and CEO, Director–$114KJan 20, 2026
Keith Lamont CummingsChief Financial Officer–$30.7KJan 20, 2026
Lily CheungChief Human Resource Officer–$9.6KJan 20, 2026
Minnie KuoChief Operating Officer–$8.9KJan 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PLRX short interest

Moderate short interest. 7.9% of PLRX shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 42%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.88M PLRX shares were sold short, 7.9% of the shares outstanding, up 5.3% from the report before. At the average daily volume of 301,369 shares, buying them all back would take about 16.2 trading days (days to cover).

Shares short, % of all shares

7.88%May 15Oct 308.44%

Days to cover

16.2May 15Oct 3018.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.88M7.88%+5%301,36916.2
Oct 15, 20264.63M7.48%+9%447,36910.4
Sep 30, 20264.25M6.86%+15%372,37211.4
Sep 15, 20263.69M5.96%+13%416,1178.9
Aug 31, 20263.28M5.29%+18%456,2717.2
Aug 14, 20262.77M4.47%-1%361,7847.7
Jul 31, 20262.81M4.53%-1%490,0965.7
Jul 15, 20262.82M4.56%+9%862,1753.3
Jun 30, 20262.58M4.17%-8%367,5547.0
Jun 15, 20262.82M4.55%-18%537,7205.2
May 29, 20263.44M5.55%-0%568,8526.0
May 15, 20263.44M5.56%+0%329,82110.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Pliant Therapeutics company events

Pliant Therapeutics filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Aug 11, 2026.

  1. Aug 11, 2026ResultsReleased financial results. Filing
  2. Jul 13, 2026LeadershipThe Board of Directors of Pliant Therapeutics, Inc. increased the authorized size of the Board from seven to nine members, and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed each of Robert Iannone, M.D., M.S.C.E. as a Class I director, and… Filing
  3. Jun 11, 2026VoteReported shareholder vote results. Filing
  4. May 11, 2026ResultsReleased financial results. Filing
  5. Apr 17, 2026LeadershipDavid E.I. Pyott, a Class I director on the Board of Directors of Pliant Therapeutics, Inc. and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and Chair of the Nominating… Filing
  6. Mar 30, 2026AnnouncementAs previously disclosed, on March 30, 2026, Pliant Therapeutics, Inc. entered into a Sales Agreement, or the 2026 Sales Agreement, with Leerink Partners LLC, as sales agent, with respect to an at-the-market offering program to sell shares of the Company’s common stock from time to time through the… Filing
  7. Mar 11, 2026ResultsReleased financial results. Filing
  8. Mar 3, 2026AgreementThe information set forth in Item 3.03 of this Current Report is incorporated into this Item 1.01 by reference. Filing
  9. Dec 16, 2025LeadershipPliant Therapeutics, Inc.’s Board of Directors appointed Minnie Kuo as Chief Operating Officer, effective immediately. Filing
  10. Dec 8, 2025LeadershipPliant Therapeutics, Inc. notified Éric Lefebvre, M.D., Chief Medical Officer, that Dr. Lefebvre’s employment with the Company will terminate effective December 15, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Pliant Therapeutics financials

Famous investors that hold PLRX

5 of the 50 well-known investors we track reported holding PLRX in their latest 13F filing. The largest position is Jim Simons's, worth $2.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.05M$2.2M0.0%+0%
Ken Griffin · Citadel AdvisorsQ3 2026319,820$345K0.0%-85%
Paul Tudor Jones · Tudor Investment CorpQ3 202629,729$32.1K0.0%No change
Israel Englander · Millennium ManagementQ3 202616,907$18.3K0.0%-97%
Steve Cohen · Point72 Asset ManagementQ3 202611,117$12K0.0%-45%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Pliant Therapeutics, Inc. (PLRX) stock

Who owns the most PLRX stock?

The largest reported owner of Pliant Therapeutics, Inc. (PLRX) is Tang Capital Management LLC, with 9.9% of the company. In total, 85 funds and institutions reported holding PLRX at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are PLRX insiders buying or selling?

In the last 12 months, PLRX insiders reported no open-market purchases and 4 sales worth $164K. The latest trade was on Jan 20, 2026. See every trade.

What is the short interest in PLRX?

As of Oct 30, 2026, 4.88M PLRX shares were sold short, 7.9% of the shares outstanding, up 5.3% from the report before. At the average daily volume of 301,369 shares, buying them all back would take about 16.2 trading days (days to cover). See the history.

Which famous investors hold PLRX?

5 of the 50 well-known investors we track reported PLRX in their latest 13F filing, including Jim Simons, Ken Griffin, Paul Tudor Jones. The largest position is worth $2.2M. See all holders.

Executive pay

Pliant Therapeutics's chief executive was paid a total of $5.5M for the year ended Dec 31, 2025, down 17% from $6.6M the year before. In the last 12 months, Pliant Therapeutics's executives and directors bought no stock on the open market and sold $164K.

Chief executive, total pay$5.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$2.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.